GlucoTrack, Inc.

GCTK Healthcare Medical Devices

EPS
+92.1%
Free cash flow
+3.42%
Total debt
+777.8%

Quarter to June 2026, against a year earlier

0.30 0.08 −21.05%
Market cap
$1.7M
P/E
0.0×
Fwd P/E
−17.8×
Dividend yield
—
F-score
3/9
Altman Z
26019048.63
Beneish M
2.40
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
— — — — — — 3 1 2 2
P/E ratio
— — — — — — 0.00 0.00 0.00 0.00
Altman Z-Score
— — — — — — 26,019,048.63 827,344.05 193,408.61 757,570.46
P/S ratio
— — — — — — 522,885,375.00 9,303,494.32 24,952,324.40 27,686,110.20
P/FCF ratio
— — — — — — 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
— — — — — — (301.18) (505.41) (145.73) (64.35)
P/Operating CF
— — — — — — (136,547,593.22) (4,507,473.85) (18,663,578.68) (17,537,881.93)
Beneish M-Score
— — — — — — 2.40 (14.97) (15.03) 0.36
P/B ratio
— — — — — — 0.00 0.00 0.00 0.00
EV/Sales
— — — — — — 522,885,374.04 9,303,494.51 24,952,324.66 27,686,110.27
EV/EBITDA
— — — — — — 0.00 0.00 0.00 0.00
EV/FCF
— — — — — — (27,730,789.85) (1,002,969.78) (2,486,583.85) (3,142,517.13)
Current Ratio
1.61 4.52 3.22 2.35 6.91 7.61 0.32 0.10 0.33 0.86
Net Debt/EBITDA
0.25 0.37 0.61 0.48 1.46 3.09 0.02 (0.01) (0.01) 0.00
Debt/Equity
1.21 (0.02) 0.06 0.16 0.05 0.03 (0.24) (0.06) (0.01) (0.01)
ROE
381.20% 461.02% (320.62%) (138.92%) (57.54%) (71.23%) 164.10% 69.06% 75.05% 60.38%
ROA
(281.60%) (417.03%) (193.30%) (101.92%) (48.21%) (46.08%) (394.13%) (569.80%) (500.21%) (235.53%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(639.45%) (492.52%) (209.78%) (315.43%) (76.87%) (29.85%) 247.61% 243.51% 460.68% 5,997.45%
Average Days of Receivables
— — — — — 0.00 122.84 191.31 75.41 54.96
Earnings Yield
— — — — — — 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — — — — 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(740.87) (62,970.00) (65,580.00) (0.24) (0.24) (0.24) (0.03) (0.58) (0.94) (0.93)
Book value per Share
136.62 (65,000.00) 31,970.00 0.08 0.33 0.60 (0.01) (0.34) (2.64) (1.89)
Free Cash Flow
(15.34) (12.59) (6.56) (3.73) (3.77) (3.55) (3.92) (4.90) (5.91) (5.39)
EV/EBIT
— — — — — — 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026